Imfinzi 500 mg is the brand name for durvalumab, an immunotherapy (immune checkpoint inhibitor) that belongs to the PD-L1 inhibitor class.
🔹 Medical Uses:
Treatment of non-small cell lung cancer (NSCLC) at certain stages after chemotherapy and radiation.
Treatment of biliary tract cancer in combination with other medications.
🔹 How it works:
The drug disables the PD-L1 protein, which some cancer cells use to hide from the immune system, helping immune cells recognize and attack the cancer.
🔹 Warnings:
May cause immune-mediated side effects affecting the lungs, liver, kidneys, thyroid, or other organs.
The patient should be monitored regularly and any unusual symptoms should be reported to the doctor.
🔹 Administration Method:
It is administered via intravenous infusion by a physician or healthcare professional.
🔹 Medical Uses:
Treatment of non-small cell lung cancer (NSCLC) at certain stages after chemotherapy and radiation.
Treatment of biliary tract cancer in combination with other medications.
🔹 How it works:
The drug disables the PD-L1 protein, which some cancer cells use to hide from the immune system, helping immune cells recognize and attack the cancer.
🔹 Warnings:
May cause immune-mediated side effects affecting the lungs, liver, kidneys, thyroid, or other organs.
The patient should be monitored regularly and any unusual symptoms should be reported to the doctor.
🔹 Administration Method:
It is administered via intravenous infusion by a physician or healthcare professional.
Reviews
There are no reviews yet.